Pharmaceutical Manufacturing – Valsartan Tablets

The contract entails the manufacturing of Valsartan tablets in 40 MG, 80 MG, and 160 MG strengths compliant with FDA current Good Manufacturing Practices, covering all stages from formulation and tablet compression through rigorous quality control and final batch release. The work must adhere to stringent regulatory standards to ensure product safety, efficacy, and consistency, with full documentation and traceability required throughout the production lifecycle. The supplier is expected to deliver finished pharmaceutical units that meet all specified pharmacopeial and regulatory criteria for use in U.S. government healthcare programs. This subcontract is awarded under the NAICS code 325412 for Pharmaceutical Preparation Manufacturing by DLA Troop Support, a division of the Department of Defense, with a response deadline of July 23, 2026. While the place of performance and point of contact details are unspecified, the contract requires full compliance with federal procurement regulations and is open to qualified manufacturers capable of scaling production to meet DoD demand. The absence of a set-aside classification indicates competition is open to all eligible entities, and successful bidders must demonstrate proven experience in pharmaceutical manufacturing under cGMP conditions and the capacity to reliably supply the required dosage strengths on schedule.